The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study.
 
Nazli Dizman
Stock and Other Ownership Interests - Several pharmaceutical companies (I)
Consulting or Advisory Role - Vivreon Biosciences
 
Sahil Doshi
No Relationships to Disclose
 
Andrea Knezevic
Consulting or Advisory Role - ByHeart
 
Ardit Feinaj
No Relationships to Disclose
 
Nicolas Sayegh
No Relationships to Disclose
 
Charbel Hobeika
No Relationships to Disclose
 
Reza Alaghehbandan
Honoraria - Health & Wellness Innovations
 
Hal Rives
No Relationships to Disclose
 
Zeynep Zengin
No Relationships to Disclose
 
David Braun
Stock and Other Ownership Interests - CurIOS Therapeutics; Elephas Bio; Fortress Biotech (subsidiary)
Consulting or Advisory Role - 2nd.MD; Abbvie; Adept Field Solutions; Aptitude Health; AVEO; Blueprint Partnership; Bristol-Myers Squibb; Catenion; Cello Health; Charles River Associates; Compugen; CurIOS Therapeutics; Dedham Group; Defined Health; DLA Piper; Eisai; Elephas Bio; Exelixis; Insight Strategy; Link Cell Therapies; Merck; Neomorph; Octane Co.; Pfizer; Pfizer; Schlesinger Associates; Scholar Rock; Scholar Rock; Scholar Rock; Slingshot Insights; Targeted Oncology; Trinity Group
Research Funding - AstraZeneca; Exelixis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Matthew Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - Adicet Bio; AVEO; Exelixis; Merck
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - DAVA Oncology
 
Bradley McGregor
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; Exelixis; Genmab; Gilead Sciences; Loxo/Lilly; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Pfizer/EMD Serono (Inst); Seattle Genetics/Astellas (Inst)
 
Hans Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; exelixis; Lilly; Merck; Novartis; Pfizer; Surface Oncology
Research Funding - aravive (Inst); Aveo (Inst); Bristol-Myers Squibb (Inst); Hibercell (Inst); Merck (Inst); NGM Biopharmaceuticals (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer
 
Yasser Ged
Consulting or Advisory Role - AVEO; BostonGene; Bristol Myers Squibb; Eisai; Exelixis; Targeted Oncology; Targeted Oncology
 
Moshe Ornstein
Consulting or Advisory Role - AVEO; Bristol Myers Squibb Foundation; Eisai; Exelixis; Merck; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Merck
Research Funding - Aravive (Inst); Arcus Biosciences (Inst); Astellas Medivation (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); HiberCell (Inst); Merck (Inst); Pfizer (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Exelixis; Merck; Pfizer
 
Pavlos Msaouel
Honoraria - Exelixis; Mirati Therapeutics; Pfizer
Consulting or Advisory Role - Axiom Healthcare Strategies
Research Funding - Bristol-Myers Squibb (Inst); Gateway for Cancer Research (Inst); Mirati Therapeutics (Inst); Takeda (Inst)
 
Andrew Hahn
Honoraria - Binacea; Kaplan Partners in Knowledge; Medscape
Consulting or Advisory Role - AVEO; Eisai; Exelixis; Intellisphere; Janssen Scientific Affairs; Pfizer
Research Funding - Bayer; Eisai (Inst)
Travel, Accommodations, Expenses - Dava Oncology
 
Martin Voss
Consulting or Advisory Role - Affimed Therapeutics; AVEO; Eisai; Exelixis; Merck; Oncorena
Research Funding - Exelixis; Pfizer
(OPTIONAL) Uncompensated Relationships - Aravive; AstraZeneca; BMS; Genentech/Roche; NiKang Therapeutics